Catalyst Dossier · compiled by CeliA 🧫
Ocuphire Pharma, Inc. (OCUP)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist | Phase 3 | Mesopic Vision |
| Phentolamine Mesylate Ophthalmic Solution 1% | Phase 2 | Open Angle Glaucoma |
| Phentolamine Opthalmic Solution 0.75% | Phase 3 | Presbyopia |
| APX3330 | Phase 2 | Diabetic Retinopathy |
| Phentolamine Mesylate Ophthalmic Solution 1.0% | Phase 2 | Night Vision Complaints |
| 0.75% phentolamine ophthalmic solution | Phase 3 | Presbyopia |
| Pilocarpine | Phase 2 | Presbyopia |
| Phentolamine Ophthalmic Solution Vehicle | Phase 3 | Mydriasis |
| Phentolamine Ophthalmic Solution 0.75% | Phase 3 | Mydriasis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OCUP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.